Review
Virology
Cesar Henriquez-Camacho, Ana Isabel Hijas-Gomez, Carlos Risco Risco, Maria Angeles Ruiz Lapuente, Rosa Escudero-Sanchez, Victor Moreno Cuerda
Summary: There is insufficient evidence to support the superior efficacy of nucleoside analogues compared to placebo/standard-of-care in treating acute viral hepatitis.
Article
Immunology
Yao-Chun Hsu, Ming-Lun Yeh, Grace Lai-Hung Wong, Chien-Hung Chen, Cheng-Yuan Peng, Maria Buti, Masaru Enomoto, Qing Xie, Huy Trinh, Carmen Preda, Li Liu, Ka-Shing Cheung, Yee Hui Yeo, Joseph Hoang, Chung-Feng Huang, Mar Riveiro-Barciela, Ritsuzo Kozuka, Doina Istratescu, Pei-Chien Tsai, Elena Vargas Accarino, Dong-Hyun Lee, Jia-Ling Wu, Jee Fu Huang, Chia-Yen Dai, Ramsey Cheung, Wan-Long Chuang, Man-Fung Yuen, Vincent Wai-Sun Wong, Ming-Lung Yu, Mindie H. Nguyen
Summary: In patients with chronic hepatitis B treated with ETV or TDF, the occurrence of HBsAg seroclearance is rare and is associated with low-level viremia, elevated alanine aminotransferase levels, bilirubin levels, and fatty liver.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Biochemistry & Molecular Biology
Chih-Wen Huang, Chen-Ta Yang, Pei-Yuan Su, Yang-Yuan Chen, Siou-Ping Huang, Hsu-Heng Yen
Summary: This study compared the relapse rates of chronic hepatitis B patients after discontinuation of nucleos(t)ide analogues therapy with tenofovir alafenamide (TAF) and entecavir. The results showed that at 12 weeks after discontinuation, no patients in the entecavir group had relapsed, while three patients (7.9% cumulative rate) in the TAF group had relapsed. At 24 and 48 weeks, the cumulative rates of relapse in the entecavir and TAF groups were significantly different. Therefore, close monitoring of liver function and HBV DNA levels is necessary, especially within 24 weeks after discontinuation of TAF therapy.
Article
Gastroenterology & Hepatology
Chien-Wei Peng, Wen-Juei Jeng, Hwai- Yang, Yen-Chun Liu, Rong-Nan Chien, Yun-Fan Liaw
Summary: In HBeAg negative chronic hepatitis B (CHB) patients, stopping tenofovir and other nucleos(t)ide analogues (Nucs) is associated with more frequent and severe clinical relapse. This study found that switching to entecavir more than 12 weeks prior to stopping treatment can delay and reduce the occurrence of clinical relapse and flares.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Chien-Hung Chen, Cheng-Yuan Peng, Tsung-Hui Hu, Jing-Houng Wang, Chao-Hung Hung, Sheng-Nan Lu
Summary: This study compared the rates of HBsAg loss after discontinuation of entecavir and tenofovir disoproxil fumarate in patients with chronic hepatitis B. The results showed that patients who discontinued TDF had higher risks of virological and clinical relapse, as well as retreatment, compared to those who discontinued entecavir.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Man-Fung Yuen, Danny Ka-Ho Wong, Thomas Schluep, Ching-Lung Lai, Carlo Ferrari, Stephen Locarnini, Regina Cheuk-Lam Lo, Robert G. Gish, James Hamilton, Christine Wooddell, Lung Yi Mak, Bruce D. Given
Summary: The study investigated the serological, virological, and histological profiles in chronic HBV patients treated with multiple dose ARC-520. Results showed sustained and profound reductions in viral antigens and HBV RNA, with achievable HBsAg seroclearance. Immune activation was observed in some patients, and HBcAg staining was negative in all biopsied patients.
Article
Gastroenterology & Hepatology
Misako Tanaka, Takemi Akahane, Hideto Kawaratani, Nobuyuki Yorioka, Aritoshi Koizumi, Shohei Asada, Takuya Matsuda, Satoshi Iwai, Yuki Tsuji, Yukihisa Fujinaga, Norihisa Nishimura, Koh Kitagawa, Kosuke Kaji, Tadashi Namisaki, Hitoshi Yoshiji
Summary: This study aims to investigate the long-term effects of entecavir and tenofovir alafenamide fumarate on renal function in elderly patients with chronic hepatitis B in Japan. The findings suggest that the change in estimated glomerular filtration rate after treatment is significantly greater in patients aged 65 years and older compared to those younger than 65 years.
HEPATOLOGY RESEARCH
(2023)
Article
Gastroenterology & Hepatology
Stanislas Pol
Summary: This study compared the impact of tenofovir and entecavir on outcomes of patients with HBV infection, and found that there was no difference in the incidence rates of HCC, DC, LT, and other liver-related events between the two treatments.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Immunology
Minghui Li, Yuanjiao Gao, Liu Yang, Yanjie Lin, Wen Deng, Tingting Jiang, Xiaoyue Bi, Yao Lu, Lu Zhang, Ge Shen, Ruyu Liu, Shuling Wu, Min Chang, Mengjiao Xu, Leiping Hu, Rui Song, Yuyong Jiang, Wei Yi, Yao Xie
Summary: This study investigated the kinetic changes of serum, virological, and immunological markers during entecavir (ETV) antiviral therapy in HBeAg-positive chronic hepatitis B (CHB) patients. Findings suggest that baseline HBV DNA load, HBeAg, and IL-10 levels were significantly associated with ALT normalization after 48 weeks of ETV treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Infectious Diseases
Yongbin Wu, Jian Wen, Guifang Tang, Jing Zhang, Jie Xin
Summary: This study found that changes in HBV RNA levels during treatment can predict entecavir-induced HBeAg seroconversion in children with chronic hepatitis B.
JOURNAL OF INFECTION
(2021)
Article
Immunology
Jun Li, Xiao-Qin Dong, Li-Hua Cao, Zhan-Qing Zhang, Wei-Feng Zhao, Qing-Hua Shang, Da-Zhi Zhang, An-Lin Ma, Qing Xie, Hong-Lian Gui, Guo Zhang, Ying-Xia Liu, Jia Shang, Shi-Bin Xie, Yi-Qi Liu, Chi Zhang, Gui-Qiang Wang, Hong Zhao
Summary: This study investigated the factors associated with persistent viremia in patients with chronic hepatitis B receiving long-term antiviral therapy, and found that baseline HBV DNA level, Anti-HBc level, and HBeAg seropositivity were associated with persistent viremia.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)
Article
Gastroenterology & Hepatology
Hye Yeon Chon, Jae Seung Lee, Hye Won Lee, Ho Soo Chun, Beom Kyung Kim, Won Young Tak, Jun Yong Park, Young-Oh Kweon, Do Young Kim, Sang Hoon Ahn, Se Young Jang, Soo Young Park, Seung Up Kim
Summary: Both SAGE-B and CAGE-B models showed acceptable performance in predicting HCC after 5 years of AVT in Asian patients with CHB.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Hannah S. J. Choi, Grishma Hirode, Chien-Hung Chen, Tung-Hung Su, Wai-Kay Seto, Stijn Van Hees, Margarita Papatheodoridi, Sabela Lens, Grace L. H. Wong, Sylvia M. Brakenhoff, Rong-Nan Chien, Jordan J. Feld, Milan J. Sonneveld, Henry L. Y. Chan, Xavier Forns, George Papatheodoridis, Thomas Vanwolleghem, Man-Fung Yuen, Yao-Chun Hsu, Jia-Horn Kao, Markus Cornberg, Bettina E. Hansen, Wen-Jue Jeng, Harry L. A. Janssen
Summary: This study compared the relapse rates and treatment outcomes after discontinuation of therapy in chronic hepatitis B patients using entecavir (ETV) and tenofovir disoproxil fumarate (TDF). It found that TDF was associated with a higher rate of HBsAg loss, earlier virological relapse, and higher clinical relapse compared to ETV. However, the rates of HBsAg loss and retreatment were similar between the two treatment groups. Finite therapy can be considered for CHB patients on either TDF or ETV therapy.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Chan-Young Jung, Hyung Woo Kim, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim
Summary: A study compared the risk of kidney function decline in treatment-naive chronic hepatitis B patients treated with ETV and TAF, finding that the risk was significantly higher in the ETV-treated group. Further prospective randomized studies are needed to confirm these findings.
LIVER INTERNATIONAL
(2022)
Article
Gastroenterology & Hepatology
Tetsuya Hosaka, Fumitaka Suzuki, Mariko Kobayashi, Shunichiro Fujiyama, Yusuke Kawamura, Hitomi Sezaki, Norio Akuta, Masahiro Kobayashi, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada
Summary: The study found that measuring HBcrAg using an ultrasensitive assay has a better potential for predicting the development of hepatocellular carcinoma in patients with chronic hepatitis B undergoing antiviral treatment.
HEPATOLOGY COMMUNICATIONS
(2022)
Article
Surgery
Yuki Okamoto, Shiro Oka, Shinji Tanaka, Shinji Nagata, Masaki Kunihiro, Toshio Kuwai, Yuko Hiraga, Seiji Onogawa, Takeshi Mizumoto, Hideharu Okanobu, Morihisa Akagi, Kazuaki Chayama
Summary: This study investigated the clinical outcomes of hybrid ESD for colorectal tumors that met the 30 mm lesion size criterion. The salvage group had a higher perforation rate overall, but a lower rate during snaring. During the second period compared to the first, there were significantly higher complete en bloc resection rates and experienced operator rates.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
(2022)
Article
Surgery
Naruhiko Honmyo, Tsuyoshi Kobayashi, Shintaro Kuroda, Kentaro Ide, Masahiro Ohira, Hiroyuki Tahara, Hiroshi Morimoto, Naoki Tanimine, Michinori Hamaoka, Megumi Yamaguchi, Masateru Yamamoto, Daisuke Takei, Hiroshi Aikata, Kazuaki Chayama, Hideki Ohdan
Summary: This study identified risk factors for hepatocellular carcinoma (HCC) development after splenectomy for portal hypertension. The etiology of cirrhosis, presence of HCC history, and preoperative hemoglobin level were found to be associated with HCC development. The predictive model constructed in this study may assist in surveillance for HCC after splenectomy in patients with portal hypertension.
Article
Gastroenterology & Hepatology
Tongqi Qian, Naoto Fujiwara, Bhuvaneswari Koneru, Atsushi Ono, Naoto Kubota, Arun K. Jajoriya, Matthew G. Tung, Emilie Crouchet, Won-Min Song, Cesia Ammi Marquez, Gayatri Panda, Ayaka Hoshida, Indu Raman, Quan-Zhen Li, Cheryl Lewis, Adam Yopp, Nicole E. Rich, Amit G. Singal, Shigeki Nakagawa, Nicolas Goossens, Takaaki Higashi, Anna P. Koh, C. Billie Bian, Hiroki Hoshida, Parissa Tabrizian, Ganesh Gunasekaran, Sander Florman, Myron E. Schwarz, Spiros P. Hiotis, Takashi Nakahara, Hiroshi Aikata, Eisuke Murakami, Toru Beppu, Hideo Baba, Rew Warren, Sangeeta Bhatia, Masahiro Kobayashi, Hiromitsu Kumada, Austin J. Fobar, Neehar D. Parikh, Jorge A. Marrero, Steve Hategekimana Rwema, Venugopalan Nair, Manishkumar Patel, Seunghee Kim-Schulze, Kathleen Corey, Jacqueline G. O'Leary, Goran B. Klintmalm, David L. Thomas, Mohammed Dibas, Gerardo Rodriguez, Bin Zhang, Scott L. Friedman, Thomas F. Baumert, Bryan C. Fuchs, Kazuaki Chayama, Shijia Zhu, Raymond T. Chung, Yujin Hoshida
Summary: This study developed a surrogate biomarker to predict liver fibrosis progression and evaluated the effectiveness of antifibrotic drugs. Results showed that a 20-gene surrogate biomarker could accurately predict fibrosis progression within 5 years. Furthermore, rational combination therapies based on epigallocatechin gallate were identified and validated for enhanced antifibrotic effect. This biomarker has potential clinical significance for the development of antifibrotics.
Article
Peripheral Vascular Disease
Yiming Han, Tatsuya Maruhashi, Masato Kajikawa, Shinji Kishimoto, Takayuki Yamaji, Takahiro Harada, Yu Hashimoto, Farina Mohamad Yusoff, Yukiko Nakano, Kazuaki Chayama, Ayumu Nakashima, Chikara Goto, Kenichi Yoshimura, Yukihito Higashi
Summary: This study investigated the association of isolated diastolic hypertension with endothelial function according to two major hypertension guidelines. The results showed that isolated diastolic hypertension was not associated with endothelial dysfunction in individuals who were not treated with antihypertensive drugs.
HYPERTENSION RESEARCH
(2022)
Article
Peripheral Vascular Disease
Takahiro Harada, Masato Kajikawa, Tatsuya Maruhashi, Shinji Kishimoto, Takayuki Yamaji, Yiming Han, Aya Mizobuchi, Yu Hashimoto, Kenichi Yoshimura, Yukiko Nakano, Kazuaki Chayama, Chikara Goto, Farina Mohamad Yusoff, Ayumu Nakashima, Yukihito Higashi
Summary: This study revealed an inverse association between height and the risk of cardiovascular disease in Japanese men. Taller individuals had significantly higher flow-mediated vasodilation values compared to shorter individuals. Shorter individuals may require intensive interventions to reduce the risk of cardiovascular events.
HYPERTENSION RESEARCH
(2022)
Article
Gastroenterology & Hepatology
Yutaro Ogawa, Takashi Nakahara, Masafumi Ono, Takumi Kawaguchi, Hiroshi Isoda, Akira Hiramatsu, Shinsuke Uchikawa, Hatsue Fujino, Eisuke Murakami, Tomokazu Kawaoka, Masami Yamauchi, Masataka Tsuge, Kensuke Munekage, Tsunehiro Ochi, C. Nelson Hayes, Michio Imamura, Hiroshi Aikata, Hirokazu Takahashi, Takuji Torimura, Kazuaki Chayama
Summary: This study evaluated blood glucose variability in patients with chronic liver disease using a continuous glucose monitoring system (CGMS) and examined the discrepancy between hemoglobin A1c (HbA1c) levels estimated from average blood glucose levels and HbA1c. The results showed that as hepatic functional reserve decreased, average blood glucose and insulin resistance increased while HbA1c decreased. A formula was created to calculate HbA1c without using CGMS. CGMS was useful in assessing accurate glycemic control and detecting hyperglycemia and hypoglycemia. Correction of hepatic functional reserve is necessary for glycemic control in patients with chronic liver disease.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Naohiro Kamiya, Takahiko Sugimoto, Hiromi Abe-Chayama, Rie Akiyama, Yasunori Tsuboi, Akira Mogami, Michio Imamura, C. Nelson Hayes, Kazuaki Chayama
Summary: In this study, a robust method was established to untie mature rcDNA into linear DNA, which can be used for quantification and visualization of cccDNA. Precise quantification was achieved by combining the method with plasmid-safe DNase and T5 exonuclease preprocessing and digesting cccDNA with a restriction enzyme. The method was successfully applied to an infection model and demonstrated the possibility of evaluating cccDNA levels accurately.
JOURNAL OF GENERAL VIROLOGY
(2022)
Correction
Gastroenterology & Hepatology
Heather J. Cordell, James J. Fryett, Kazuko Ueno, Rebecca Darlay, Yoshihiro Aiba, Yuki Hitomi, Minae Kawashima, Nao Nishida, Seik-Soon Khor, Olivier Gervais, Yosuke Kawai, Masao Nagasaki, Katsushi Tokunaga, Ruqi Tang, Yongyong Shi, Zhiqiang Li, Brian D. Juran, Elizabeth J. Atkinson, Alessio Gerussi, Marco Carbone, Rosanna Asselta, Angela Cheung, Mariza de Andrade, Aris Baras, Julie Horowitz, Manuel A. R. Ferreira, Dylan Sun, David E. Jones, Steven Flack, Ann Spicer, Victoria L. Mulcahy, Jinyoung Byun, Younghun Han, Richard N. Sandford, Konstantinos N. Lazaridis, Christopher I. Amos, Gideon M. Hirsch, Michael F. Seldin, Pietro Invernizzi, Katherine A. Siminovitch, Xiong Ma, Minoru Nakamura, George F. Mells
JOURNAL OF HEPATOLOGY
(2022)
Article
Infectious Diseases
Haruna Hatooka, Yumi Shimomura, Michio Imamura, Yuji Teraoka, Kei Morio, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Grace Naswa Makokha, Daiki Miki, Masataka Tsuge, Akira Hiramatsu, Hiromi Abe-Chayama, C. Nelson Hayes, Hiroshi Aikata, Shinji Tanaka, Kazuaki Chayama
Summary: The study developed an antibody against preS1 and an ELISA system for measuring serum preS1 levels. PreS1 may serve as a novel tool to predict the need for antiviral therapy in HBeAg-negative HBV-infected patients.
JOURNAL OF INFECTION
(2022)
Article
Virology
Toshitada Takemori, Akiko Sugimoto-Ishige, Hironori Nishitsuji, Yushi Futamura, Michishige Harada, Tomomi Kimura-Someya, Takehisa Matsumoto, Teruki Honma, Miho Tanaka, Masami Yaguchi, Kyoichi Isono, Haruhiko Koseki, Hiroyuki Osada, Daiki Miki, Takashi Saito, Takashi Tanaka, Takehiro Fukami, Toshio Goto, Mikako Shirouzu, Kunitada Shimotohno, Kazuaki Chayama
Summary: Entry inhibitors are being developed to enhance the treatment of HBV patients with oral nucleoside/nucleotide analogues (NA). Therapeutic MAbs with neutralizing activity against HBs antigens have been developed to amplify the effectiveness of NA therapy. Targeting NTCP can provide an effective treatment option for patients with chronic hepatitis B, regardless of viral genotype, mutations, and the presence of subviral particles.
JOURNAL OF VIROLOGY
(2022)
Review
Gastroenterology & Hepatology
C. Nelson Hayes, Michio Imamura, Junko Tanaka, Kazuaki Chayama
Summary: Since its discovery in 1989, the road to a cure for hepatitis C virus (HCV) has been slow, but most patients can now expect to achieve a sustained virological response (SVR). Adverse events are rare or mild, and patients with compensated cirrhosis and other co-morbidities are often eligible for treatment. However, a small number of patients fail to eradicate the virus even after retreatment.
LIVER INTERNATIONAL
(2022)
Article
Multidisciplinary Sciences
Kenji Yamaoka, Kenichiro Kodama, Tomokazu Kawaoka, Masanari Kosaka, Yusuke Johira, Yuki Shirane, Ryoichi Miura, Shigeki Yano, Serami Murakami, Kei Amioka, Kensuke Naruto, Yuwa Ando, Yumi Kosaka, Shinsuke Uchikawa, Takuro Uchida, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Wataru Okamoto, Masami Yamauchi, Daiki Miki, Michio Imamura, Shoichi Takahashi, Akiko Nagao, Kazuaki Chayama, Hiroshi Aikata
Summary: The study found that assessing body composition before and after lenvatinib treatment using BIA can be useful in predicting prognosis in patients with hepatocellular carcinoma.
Article
Endocrinology & Metabolism
Takayuki Yamaji, Takahiro Harada, Yu Hashimoto, Yukiko Nakano, Masato Kajikawa, Kenichi Yoshimura, Gaku Aoki, Kazuaki Chayama, Chikara Goto, Aya Mizobuchi, Yiming Han, Farina Mohamad Yusoff, Shinji Kishimoto, Tatsuya Maruhashi, Ayumu Nakashima, Yukihito Higashi
Summary: This study investigated the relationship between HbA1c levels and vascular function in patients with type 2 diabetes mellitus receiving antidiabetic drug treatment. Results showed an inverted U-shaped association between HbA1c levels and FMD, with both low (<6.5%) and high (>= 8.0%) HbA1c levels associated with endothelial dysfunction, while vascular smooth muscle function was similar regardless of HbA1c levels.
JOURNAL OF DIABETES INVESTIGATION
(2022)
Article
Gastroenterology & Hepatology
Man-Fung Yuen, Jeong Heo, Hiromitsu Kumada, Fumitaka Suzuki, Yoshiyuki Suzuki, Qing Xie, Jidong Jia, Yoshiyasu Karino, Jinlin Hou, Kazuaki Chayama, Michio Imamura, Judy Y. Lao-Tan, Seng Gee Lim, Yasuhito Tanaka, Wen Xie, Jung-Hwan Yoon, Zhongping Duan, Masayuki Kurosaki, Sung-Jae Park, Madalinee Eternity Labio, Rajneesh Kumar, Young-Oh Kweon, Hyung Joon Yim, Yu Tao, Jennifer Cremer, Robert Elston, Matt Davies, Sharon Baptiste-Brown, Kelong Han, Fiona M. Campbell, Melanie Paff, Dickens Theodore
Summary: This study evaluated the safety and efficacy of GSK3389404, a drug targeting chronic HBV infection. The results showed that GSK3389404 can reduce the production of HBV viral proteins, although no optimal dosing regimen was identified.
JOURNAL OF HEPATOLOGY
(2022)
Article
Genetics & Heredity
Hiroki Kiyose, Hidewaki Nakagawa, Atsushi Ono, Hiroshi Aikata, Masaki Ueno, Shinya Hayami, Hiroki Yamaue, Kazuaki Chayama, Mihoko Shimada, Jing Hao Wong, Akihiro Fujimoto
Summary: This study utilized the Oxford Nanopore sequencer to analyze cDNA sequences from hepatocellular carcinoma and matched non-cancerous livers, revealing numerous novel transcripts and thousands of differentially expressed transcripts. Experimental results demonstrated that differentially expressed transcripts can promote cell growth, and fusion gene detection uncovered novel fusion events.